Logo Image

Jeffrey Bratberg, PharmD, FAPhA, University of Rhode Island College of Pharmacy

University of Rhode Island College of Pharmacy

Articles by Jeffrey Bratberg, PharmD, FAPhA, University of Rhode Island College of Pharmacy

Final Thoughts on the Opioid Crisis and Normalizing Naloxone

ByPeter Salgo, MD, Columbia University Irving Medical Center ,Jeremy Adler, DMSc, PA-C, DFAAPA, Pacific Pain Medicine Consultants ,Jeffrey Bratberg, PharmD, FAPhA, University of Rhode Island College of Pharmacy ,Theresa Mallick-Searle, MS, RN-BC, ANP-BC, Stanford Health Care ,Charles Argoff, MD, Albany Medical Center

The multidisciplinary panel of experts share final thoughts on strategies to normalize naloxone and decrease barriers to its obtainment and utilization.

Pain Contracts vs Agreements Between Clinicians and Patients

ByPeter Salgo, MD, Columbia University Irving Medical Center ,Jeremy Adler, DMSc, PA-C, DFAAPA, Pacific Pain Medicine Consultants ,Jeffrey Bratberg, PharmD, FAPhA, University of Rhode Island College of Pharmacy ,Theresa Mallick-Searle, MS, RN-BC, ANP-BC, Stanford Health Care ,Charles Argoff, MD, Albany Medical Center

Charles Argoff, MD, leads a discussion on the use of pain contracts versus pain agreements between clinicians and patients to bring about desired outcomes.

Peer to Peer Discussion Initiatives and Telemedicine Impact

ByPeter Salgo, MD, Columbia University Irving Medical Center ,Jeremy Adler, DMSc, PA-C, DFAAPA, Pacific Pain Medicine Consultants ,Jeffrey Bratberg, PharmD, FAPhA, University of Rhode Island College of Pharmacy ,Theresa Mallick-Searle, MS, RN-BC, ANP-BC, Stanford Health Care ,Charles Argoff, MD, Albany Medical Center

Experts discuss the need for and impact of peer-to-peer discussion initiatives, as well as the impact telemedicine utilization has had on the opioid crisis.

Role and Impact of Prescription Monitoring Programs

ByPeter Salgo, MD, Columbia University Irving Medical Center ,Jeremy Adler, DMSc, PA-C, DFAAPA, Pacific Pain Medicine Consultants ,Jeffrey Bratberg, PharmD, FAPhA, University of Rhode Island College of Pharmacy ,Theresa Mallick-Searle, MS, RN-BC, ANP-BC, Stanford Health Care ,Charles Argoff, MD, Albany Medical Center

Experts share insights on how they have utilized Prescription Monitoring Programs to combat the opioid crisis and improve the safety of prescribed opioids.

Essential Patient Education Considerations for Naloxone

ByPeter Salgo, MD, Columbia University Irving Medical Center ,Jeremy Adler, DMSc, PA-C, DFAAPA, Pacific Pain Medicine Consultants ,Jeffrey Bratberg, PharmD, FAPhA, University of Rhode Island College of Pharmacy ,Theresa Mallick-Searle, MS, RN-BC, ANP-BC, Stanford Health Care ,Charles Argoff, MD, Albany Medical Center

Experts share approaches to normalize conversations about naloxone with patients, as well as share important considerations for maximizing naloxone education.

Are Recommendations Infringing Upon Practice Autonomy?

ByPeter Salgo, MD, Columbia University Irving Medical Center ,Jeremy Adler, DMSc, PA-C, DFAAPA, Pacific Pain Medicine Consultants ,Jeffrey Bratberg, PharmD, FAPhA, University of Rhode Island College of Pharmacy ,Theresa Mallick-Searle, MS, RN-BC, ANP-BC, Stanford Health Care ,Charles Argoff, MD, Albany Medical Center

Multidisciplinary panel of clinicians discuss whether recommendations made by national, state, and local agencies infringes upon clinical practice autonomy. 

December 2020 CDC Health Alert Highlights and Implementation

ByPeter Salgo, MD, Columbia University Irving Medical Center ,Jeremy Adler, DMSc, PA-C, DFAAPA, Pacific Pain Medicine Consultants ,Jeffrey Bratberg, PharmD, FAPhA, University of Rhode Island College of Pharmacy ,Theresa Mallick-Searle, MS, RN-BC, ANP-BC, Stanford Health Care ,Charles Argoff, MD, Albany Medical Center

Jeffrey Bratberg, PharmD, FAPhA, and Joshua Lynch, DO, EMT-P, FAAEM, FACEP, discuss highlights from the December 2020 CDC Health Alert and application.

Barriers to Naloxone Prescribing, Dispensing, and Utilization

ByPeter Salgo, MD, Columbia University Irving Medical Center ,Jeremy Adler, DMSc, PA-C, DFAAPA, Pacific Pain Medicine Consultants ,Jeffrey Bratberg, PharmD, FAPhA, University of Rhode Island College of Pharmacy ,Theresa Mallick-Searle, MS, RN-BC, ANP-BC, Stanford Health Care ,Charles Argoff, MD, Albany Medical Center

Experts address barriers to overcome regarding naloxone prescribing, dispensing, and utilization that they have seen in the community.

Normalizing the Conversation about Naloxone with the Public

ByPeter Salgo, MD, Columbia University Irving Medical Center ,Jeremy Adler, DMSc, PA-C, DFAAPA, Pacific Pain Medicine Consultants ,Jeffrey Bratberg, PharmD, FAPhA, University of Rhode Island College of Pharmacy ,Theresa Mallick-Searle, MS, RN-BC, ANP-BC, Stanford Health Care ,Charles Argoff, MD, Albany Medical Center

Multidisciplinary expert panel share perspectives on stigmatization and normalization of the conversation about naloxone between clinicians and patients.

Improving the Accessibility of Naloxone and Potential Impact

ByPeter Salgo, MD, Columbia University Irving Medical Center ,Jeremy Adler, DMSc, PA-C, DFAAPA, Pacific Pain Medicine Consultants ,Jeffrey Bratberg, PharmD, FAPhA, University of Rhode Island College of Pharmacy ,Theresa Mallick-Searle, MS, RN-BC, ANP-BC, Stanford Health Care ,Charles Argoff, MD, Albany Medical Center

Joshua Lynch, DO, EMT-P, FAAEM, FACEP, shares ways to improve naloxone accessibility, and Theresa Mallick-Searle, MS, RN-BC, ANP-BC, discusses stigmatization.

Implementing Protocols, Policies, and Programs to Save Lives

ByPeter Salgo, MD, Columbia University Irving Medical Center ,Jeremy Adler, DMSc, PA-C, DFAAPA, Pacific Pain Medicine Consultants ,Jeffrey Bratberg, PharmD, FAPhA, University of Rhode Island College of Pharmacy ,Theresa Mallick-Searle, MS, RN-BC, ANP-BC, Stanford Health Care ,Charles Argoff, MD, Albany Medical Center

Experts weigh in on protocols, policies, and programs that influence patient safety and address when a conversation should ensue with patients about naloxone.

New Labeling Requirements Put Forth by the FDA for Opioids

ByPeter Salgo, MD, Columbia University Irving Medical Center ,Jeremy Adler, DMSc, PA-C, DFAAPA, Pacific Pain Medicine Consultants ,Jeffrey Bratberg, PharmD, FAPhA, University of Rhode Island College of Pharmacy ,Theresa Mallick-Searle, MS, RN-BC, ANP-BC, Stanford Health Care ,Charles Argoff, MD, Albany Medical Center

Theresa Mallick-Searle, MS, RN-BC, ANP-BC, shares her perspective on the new labeling requirements put forth by the FDA for opioids in regards to naloxone.

Risks for Accidental Opioid Overdose Seen in the Community

ByPeter Salgo, MD, Columbia University Irving Medical Center ,Jeremy Adler, DMSc, PA-C, DFAAPA, Pacific Pain Medicine Consultants ,Jeffrey Bratberg, PharmD, FAPhA, University of Rhode Island College of Pharmacy ,Theresa Mallick-Searle, MS, RN-BC, ANP-BC, Stanford Health Care ,Charles Argoff, MD, Albany Medical Center

Joshua Lynch, DO, EMT-P, FAAEM, FACEP, highlight risks he has seen in the community for unintended users as well as patients for accidental opioid overdose.

Opioid Crisis Misconceptions and Unintended Consequences

ByPeter Salgo, MD, Columbia University Irving Medical Center ,Jeremy Adler, DMSc, PA-C, DFAAPA, Pacific Pain Medicine Consultants ,Jeffrey Bratberg, PharmD, FAPhA, University of Rhode Island College of Pharmacy ,Theresa Mallick-Searle, MS, RN-BC, ANP-BC, Stanford Health Care ,Charles Argoff, MD, Albany Medical Center

Jeffrey Bratberg, PharmD, FAPhA, leads discussion tackling common opioid-related misconceptions as well as unintended consequences of the opioid crisis.

Current State of the Opioid Crisis: Multifaceted Point of View

ByPeter Salgo, MD, Columbia University Irving Medical Center ,Jeremy Adler, DMSc, PA-C, DFAAPA, Pacific Pain Medicine Consultants ,Jeffrey Bratberg, PharmD, FAPhA, University of Rhode Island College of Pharmacy ,Theresa Mallick-Searle, MS, RN-BC, ANP-BC, Stanford Health Care ,Charles Argoff, MD, Albany Medical Center

Jeremy Adler, DMSc, PA-C, DFAAPA, leads discussion on elements that negatively impacts the quality of care for patients requiring pain management.

Unmet Needs and the Impact of COVID-19 on the Opioid Crisis

ByPeter Salgo, MD, Columbia University Irving Medical Center ,Jeremy Adler, DMSc, PA-C, DFAAPA, Pacific Pain Medicine Consultants ,Jeffrey Bratberg, PharmD, FAPhA, University of Rhode Island College of Pharmacy ,Theresa Mallick-Searle, MS, RN-BC, ANP-BC, Stanford Health Care ,Charles Argoff, MD, Albany Medical Center

Experts discuss opioid crisis complexities, such as the able to manage pain appropriately and the impact of social and structural determinates of health.

Latest Updated Articles